ClinicalTrials.gg
TerminatedNCT02856373Redress VTUpdated May 6, 2020

Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular Arrhythmias

A Phase 2 interventional study of RNS and RDN in Arrhythmias, Cardiac, sponsored by Diagram B.V.. Terminated at 1 site in Netherlands. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-06.

Sponsored by Diagram B.V. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Low enrollment number

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Mar 2015, registered Jun 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Arrhythmias, Cardiac with a site in Netherlands — 13 open to participants now, 18 under way, none of them phase 3. Arrhythmias, Cardiac · Netherlands.

Enrollment
31st of 33
9 · median 240
Started
2015
with 3 others
Phase 2
5 of 72
3 open now
Registered
33rd of 72
by date

Among the 72 studies in Arrhythmias, Cardiac with a site in Netherlands, this one is the 31st largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2015, is one of 5 in phase 2, and was the 33rd registered.

Arrhythmias, Cardiac

1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

13 of the 72 studies in Arrhythmias, Cardiac with a site in Netherlands are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Arrhythmias, Cardiac with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale:

Sympathetic activity plays an important role in the pathogenesis of ventricular tachyarrhythmia. Previous studies have shown evidence of significant heritable influences on individual responses to adrenergic stimulation. Catheter-based renal sympathetic denervation (RDN) is a novel treatment option for patients with resistant hypertension, proved to reduce local and whole-body sympathetic activity. The investigators hypothesize that percutaneous transluminal electrical stimulation of the sympathetic nerve bundles in the renal arteries will cause ventricular arrhythmias and renal denervation will suppress these arrhythmias in patients with sympathetic ventricular arrhythmias.

Objective:

This study will investigate the effects of renal nerve stimulation before and after percutaneous transluminal RDN on cardiac excitable properties including induction of ventricular tachy-arrhythmias before and after RDN in six studies, i.e. patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT syndrome and arrhythmogenic right ventricular cardiomyopathy (ARVC), sympathetically driven ventricular arrhythmias, hypertrophic cardiomyopathy (HCM), dilated non-ischemic cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). The aim of the six studies is to assess the anti-arrhythmic effects of RDN in patients with sympathetic ventricular tachy-arrhythmias.

Study design:

Investigator initiated, multi centre, six pretest-posttest design studies.

Study population:

Patients with recurrent sympathetically driven ventricular arrhythmia despite optimal pharmacological therapy. Patients should be diagnosed with CPVT and certain types of long QT syndrome, ARVC, HCM, DCM and ICM. Eligible patients will be in the age category of 18-85 year.

Intervention:

RDN will be performed according to routine clinical practice. Prior to the ablation procedure, catheter mapping of the renal arteries will be performed according to routine clinical practice. Clinical and biological responses to transluminal electrical renal nerve stimulation will be assessed before and after RDN.

Study endpoints:

  • Main procedural study endpoint: Induction of ventricular arrhythmias in response to renal nerve stimulation prior to RDN and absence of renal nerves stimulation induced ventricular arrhythmias after RDN.
  • Main clinical study endpoint: Development of ventricular arrhythmia during exercise stress testing performed 6 months after procedure.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

In several studies, it was shown that RDN was safe. The intervention resulted in significantly better control of blood pressure with less medication, and beneficial changes in heart rate variability, autonomic sympathetic balance, renal arteriolar function, and a higher success of atrial fibrillation prevention. In case reports and case series, RDN had a favourable effect in patients with sympathetic drug refractory ventricular tachy-arrhythmias.

03

Conditions studied

  • Arrhythmias, Cardiac

Keywords

  • Denervation
  • Renal Artery
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is willing and able to comply with the protocol and has provided written .
  2. The patient falls within the target group as stated in 4.1.
  3. Patient is an acceptable candidate for RDN treatment
  4. Patient is 18-85 years of age
  5. Documentation of ventricular arrhythmia (, rhythm strip or ICD interrogation)

Exclusion criteria

Exclusion Criteria:

  1. to anticoagulation therapy or heparin.
  2. Previous selective cardiac sympathetic denervation or previous RDN procedure.
  3. Acute coronary syndrome, cardiac surgery, PCI or stroke within 3 months prior to enrolment.
  4. Untreated hypothyroidism or hyperthyroidism.
  5. More than grade 1/3 valvular regurgitation and/or significant valve stenosis (moderate or severe).
  6. Severe LV dysfunction ( \<20% and/or grade 3/4 diastolic dysfunction).
  7. Enrolment in another drug or device study.
  8. Woman currently pregnant or breastfeeding or not using reliable measures during fertile age.
  9. Mental or physical inability to participate in the study.
  10. Planned cardiovascular intervention.
  11. ≤ 12 months.
  12. Renal artery stenosis >50% of the arterial lumen, or renal artery lumen ≤3 mm.
  13. Complex renal artery
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Other
    CPVT

    catecholaminergic polymorphic ventricular tachycardia (CPVT) patients

    Procedure: RNS and RDN

  • Other
    long QT syndrome

    long QT syndrome patients

    Procedure: RNS and RDN

  • Other
    ARVC

    arrhythmogenic right ventricular cardiomyopathy (ARVC) patients

    Procedure: RNS and RDN

  • Other
    HCM

    hypertrophic cardiomyopathy (HCM) patients

    Procedure: RNS and RDN

  • Other
    DCM

    dilated non-ischemic cardiomyopathy (DCM) patients

    Procedure: RNS and RDN

  • Other
    ICM

    ischemic cardiomyopathy (ICM) patients

    Procedure: RNS and RDN

Interventions

  • ProcedureRNS and RDN

    The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

06

What researchers measure

Primary outcomes

  1. Induction of ventricular arrhythmias (e.g. ventricular tachycardia and ventricular fibrillation)

    Induction of ventricular arrhythmias in response to RNS prior to RDN and absence of RNS induced ventricular arrhythmias after RDN

    Time frame: A few minutes before RDN RNS will be performed. Time frame before RDN: 0-10 min. after RNS and before RDN. Time frame after RDN: 0-10 min.

  2. Development of ventricular arrhythmia

    Development of ventricular arrhythmia during exercise stress testing performed 6 months after procedure/intervention

    Time frame: 6 months after procedure/intervention

Secondary outcomes

  1. Time to first detection of ventricular arrhythmia or appropriate ICD therapy

    Time to first detection of ventricular arrhythmia or appropriate ICD therapy with the monitoring period starting immediately after the intervention.

    Time frame: procedure/intervention-12 month follow up

  2. Changes in ventricular refractoriness (frequency)

    Changes in ventricular refractoriness (frequency, beats/min) to programmed electrical stimulation in the setting of routine electrophysiological study before and directly (0-10 min) after RDN.

    Time frame: procedure/intervention

  3. Changes in ventricular refractoriness (duration)

    Changes in ventricular refractoriness (duration, sec) to programmed electrical stimulation in the setting of routine electrophysiological study before and directly (0-10 min) after RDN.

    Time frame: procedure/intervention

  4. Number of ventricular arrhythmias

    Inducibility (number) of ventricular arrhythmias to programmed electrical stimulation in the setting of routine electrophysiological study before and after RDN.

    Time frame: procedure/intervention

  5. Ventricular arrhythmia burden

    Ventricular arrhythmia burden after 6 and 12 months of follow-up in patients with ICD or continuous rhythm monitoring with a loop recorder. The monitoring period starts immediately after the intervention.

    Time frame: procedure/intervention- 6,12 months follow up

  6. Blood pressure

    Blood pressure at 6 and 12 months after the intervention

    Time frame: 6-12 months follow up

  7. Number of (Supra-)Ventricular arrhythmias induced by exercise testing

    Number of (Supra-)Ventricular arrhythmias induced by exercise testing

    Time frame: baseline- 6 months follow up

  8. (Supra-)Ventricular arrhythmias response changes (frequency) induced by exercise testing

    (Supra-)Ventricular arrhythmias response changes (frequency, beats/min) induced by exercise testing

    Time frame: baseline- 6 months follow up

  9. (Supra-)Ventricular arrhythmias response changes (duration) induced by exercise testing

    (Supra-)Ventricular arrhythmias response changes (duration, sec) induced by exercise testing

    Time frame: baseline- 6 months follow up

  10. Changes in heart rate variability

    Changes in heart rate variability measures tested by Holter monitoring compared to measurement before the intervention

    Time frame: baseline- 3, 6 and 12 month follow up

  11. Changes in prevalence of events

    Changes in prevalence of events (hospital admission for VT or appropriate ICDshock) in the period of one year after intervention compared to a one year period before intervention.

    Time frame: 12 month before procedure/intervention-12 month follow up

  12. Change in blood pressure

    Change in blood pressure compared to measurement before the intervention

    Time frame: baseline- 6, 12 month follow up

  13. Heart rate response changes induced by exercise testing

    Heart rate response changes induced by exercise testing

    Time frame: baseline- 6 months follow up

  14. Blood pressure response changes induced by exercise testing

    Blood pressure response changes induced by exercise testing

    Time frame: baseline-6 months follow up

07

Study locations

1 site
  • A. Elvan
    Zwolle, Overijssel 8025AB, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in May 2020, 62 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2016
First posted
Aug 4, 2016
StartActual
Mar 3, 2015
Primary completionActual
May 4, 2020
CompletionActual
May 4, 2020
Last update
May 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02856373
Lead sponsor
Diagram B.V.
Responsible party
Sponsor
First posted
Aug 4, 2016
Start date
Mar 3, 2015
Primary completion
May 4, 2020
Completion
May 4, 2020
Last update
May 6, 2020

Study contacts

Arif Elvan, MD, PhD
principal investigator · Isala, department of Cardiology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion